



Otezla® (apremilast) – New warning

- On June 29, 2017, the FDA approved an update to the *Warnings and Precautions* section of the [Otezla \(apremilast\)](#) drug label regarding the risk of diarrhea, nausea and vomiting.
- Otezla is approved to treat adult patients with active psoriatic arthritis, and patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
- There have been postmarketing reports of severe diarrhea, nausea, and vomiting associated with the use of Otezla.
 - Most events occurred within the first few weeks of treatment.
 - In some cases patients were hospitalized.
 - Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting.
 - Patients who are more susceptible to complications of diarrhea or vomiting should be monitored.
 - Patients who reduced dosage or discontinued Otezla generally improved quickly.
 - If patients develop severe diarrhea, nausea, or vomiting, then consider Otezla dose reduction or suspension.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.